川芎嗪与血塞通联合治疗缺血性脑卒中临床疗效分析

Analysis of Clinical Efficacy of Ligustrazine and Xuesaitong on the Treatment of Ischemic Stroke

目的:探讨川芎嗪与血塞通联合治疗缺血性脑卒中的临床疗效及安全性。方法:将80例缺血性脑卒中患者随机分为观察组和对照组,观察组给予川芎嗪与血塞通联合治疗,对照组给予单一血塞通治疗,观察两组患者治疗前后神经功能缺损情况,并进行疗效评定。结果:观察组治疗后神经功能缺损评分明显低于对照组(P<0.05);观察组总有效率为93.45%,明显高于对照组的79.41%(P<0.05);两组患者治疗期间均未见与药物相关不良反应。结论:川芎嗪与血塞通联合治疗缺血性脑卒中具有疗效好、不良反应少等优点,可作为目前治疗缺血性脑卒中的一种首选方案。

@@@@Objective:To investigate the clinical efficacy and safety of Ligustrazine and Xuesaitong on the treatment of ischemic stroke. Method:80 cases of ischemic stroke were randomly divided into the observation group and the control group. The observation group was treated with Ligustrazine and Xuesaitong,while the control group was treated solely with Xuesaitong. Observations were carried out about both groups’ nerve function defects before and after operation. And efficacies were assessed. Result:As for the observation group,its rating of post-operative nerve function defects was significantly lower than that of the control group(P<0.05). Its ORR(93.45%)was significantly higher than that of the control group(79.41%)(P<0.05). In the treatment,there were no adverse reactions concerning medicine in both groups. Conclusion:With good efficacy and few adverse reactions,Ligustrazine and Xuesaitong can serve as the priority treatment of ischemic stroke.